Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey

  title={Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey},
  author={Eric J. Stanek and C. Sanders and Katherine Johansen Taber and Mona Javaria Khalid and A Patel and Robert R. Verbrugge and Barnabie C Agatep and R E Aubert and Robert S. Epstein and Felix W. Frueh},
  journal={Clinical Pharmacology \& Therapeutics},
To develop a benchmark measure of US physicians' level of knowledge and extent of use of pharmacogenomic testing, we conducted an anonymous, cross‐sectional, fax‐based, national survey. Of 397,832 physicians receiving the survey questionnaire, 10,303 (3%) completed and returned it; the respondents were representative of the overall US physician population. The factors associated with the decision to test were evaluated using χ2 and multivariate logistic regression. Overall, 97.6% of responding… 

A Survey of Pharmacogenomics Testing Among Physicians, Pharmacists, and Researchers From China

A lack of sector standards, a Lack of clinical research, and a lack of guidelines were found to be the major factors for hindering PGx clinical application.

Primary care physicians' knowledge of and experience with pharmacogenetic testing

Primary care practitioners envision a major role for themselves in the delivery of PGx testing but recognize their lack of adequate knowledge and experience about these tests, and development of effective tools for guiding PCPs in the use ofPGx tests should be a high priority.

On the readiness of physicians for pharmacogenomics testing: an empirical assessment

The determinants of adoption of pharmacogenomics (PGx) testing by clinicians are explored, and whether this adoption differs with regard to area of specialization is assessed, and it is shown that practice specialties matter.

Knowledge and attitudes on pharmacogenetics among pediatricians

Although practical knowledge of pharmacogenetics among pediatricians in the U.S. and Japan is currently very low, their interest in clinical pharmacogenetic testing and related education is high, which will likely facilitate future implementation.

Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties

Educational resources that are clinically oriented and easily accessible are preferred by physicians, and may best support appropriate clinical implementation of pharmacogenomics.

The Implementation Process for Pharmacogenomic Testing for Cancer-Targeted Therapies

It is found that the process of ordering pharmacogenomic tests is time-consuming, expensive, and complex and processes related to ordering and obtaining insurance coverage for pharmacogenomics tests varies greatly across institutions and is time.

Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013.

Although 35% of IL28B tests overall did not influence care, the majority of tests were guideline concordant and clinically useful.

Cancer pharmacogenomics, adoption by oncologists and patient benefit.

A critical need exists to disseminate accurate and updated caPGx information to oncologists practicing in both academic and nonacademic settings.

Physician Experience with Direct-To-Consumer Genetic Testing in Kaiser Permanente

Survey of primary care and specialist physicians to assess the degree to which direct-to-consumer genetic test results were being presented to physicians and identify genetics educational needs among physicians found 85% of physicians would spend ≥2 h/year on genetics/genomics education.

Knowledge and attitudes of oncology nurses regarding pharmacogenomic testing.

  • C. Dodson
  • Medicine
    Clinical journal of oncology nursing
  • 2014
Key elements of Rogers' Diffusion of Innovation Theory play key roles in the diffusion of pharmacogenomic testing within the oncology nursing field, and assessment of these variables may benefit the widespread adoption of pharmacogensomic testing.



Physician use of genetic testing for cancer susceptibility: results of a national survey.

  • L. WideroffA. Freedman R. Ballard-Barbash
  • Medicine
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 2003
It is found that lower CST use was associated with not knowing if there were local testing and counseling facilities and the importance of establishing effective clinical approaches to test use and promoting physician education to facilitate communication with patients about cancer genetics.

Clinical and ethical considerations in pharmacogenetic testing: views of physicians in 3 "early adopting" departments of psychiatry.

Physicians at early adopting departments of psychiatry endorsed the clinical utility of pharmacogenetic testing and the use of some patient safeguards, but showed a lack of consensus about other safeguards and risks.

Patients' and physicians' perspectives on pharmacogenetic testing.

The concerns of patients and GPs differ somewhat with respect to negative psychosocial consequences, discrimination or violation of privacy, and development of information for physicians and patients would be helpful in preventing unrealistic fears or hopes.

Health care professionals' perceptions of the role of pharmacogenomic data.

The respondents to this survey appeared optimistic about the use of pharmacogenomic information, and their responses provided a proactive framework to discuss the potential use and misuse of this technology.

Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?

It is widely claimed that pharmacogenetics may form the basis of ‘personalized medicine’. We sought to determine the current utilization of pharmacogenetic testing for drug metabolizing enzymes

Barriers to translating emerging genetic research on smoking into clinical practice

Merely describing a new test to tailor smoking treatment as “genetic” poses a significant barrier to physician adoption, and the potential of novel interventions will likely go unrealized unless barriers to clinical integration are addressed.

Pharmacogenetics education in British medical schools

The quantity of undergraduate teaching of pharmacogenetics is low, but a majority of UK medical schools teach it, covering a broad scope of elements and it is encouraging that future clinicians are being provided with the knowledge to deliver pharmacogenetic teaching into clinical practice.

Primary care physicians' perceptions of barriers to genetic testing and their willingness to participate in research.

The proportion of physicians interested in participating in research to assess the safety and effectiveness of genetic tests is sufficient to make large scale, collaborative, practice-based evaluation feasible and participation in research may serve as an effective medium for physician education in genetics.

Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS.

The gap between patients' high expectations for information and healthcare professionals' current knowledge and reluctance to deliver pharmacogenetic services highlights the urgent need for better education and training of healthcare professionals in pharmacogenetics.

Pharmacogenetics in Europe: Barriers and Opportunities

It seems that one key aspect where policy can affect the clinical uptake of PGx is via sustaining large-scale industry-academia collaborations for developing and proving the utility ofPGx diagnostics.